Hypomethylation Therapy

Known as: Hypomethylating Agent-Based Therapy, Hypomethylating Therapy 
Therapies that target the activity of DNA methyltransferases. Hypomethylating agents, including azacitidine and decitabine, have been used in the… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2017
0246820012017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to… (More)
Is this relevant?
2016
2016
Although hypomethylating therapy (HMT) is the first line therapy in higher-risk myelodysplastic syndromes (MDS), predicting… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2014
2014
The introduction of reduced-intensity conditioning (RIC) regimens made it possible to offer allogeneic hematopoietic cell… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
Is this relevant?
2014
2014
Sweet's syndrome is a rare condition with potentially disabling implications, characterized by painful skin lesions due to… (More)
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2014
2014
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is… (More)
Is this relevant?
2013
2013
In order to more thoroughly analyze aberrant DNA methylation in glioma, we applied a large cohort methylation microarray… (More)
  • figure 1
  • table I
  • figure 2
  • table II
  • figure 3
Is this relevant?
2012
2012
In a Phase I/II clinical trial, 13 higher risk red blood cell-dependent myelodysplastic syndrome (MDS) patients unresponsive to… (More)
Is this relevant?
2012
2012
A 58-year-old man with a past medical history of underlying congenital aortic valve defect and hypertension was incidentally… (More)
  • figure 1
Is this relevant?
2009
2009
Decitabine is a hypomethylating agent with activity in myelodysplastic syndrome (MDS). It is largely unknown whether treatment… (More)
  • table 1
  • table 2
Is this relevant?
2001
2001
TCL1 is an oncogene activated by recurrent reciprocal translocations at chromosome segment 14q32.1 in the most common of the… (More)
Is this relevant?